Analysis of Da Jiankang International (02211.HK) Surging on Hong Kong Stock Market Hot List

Da Jiankang International (02211.HK) was included in the East Money App Hot List (Hong Kong Stock Surging List) on December 2, 2025, indicating a significant price increase in a short period [0].

Analysis shows that the stock’s popularity may benefit from the overall strong performance of the healthcare sector:

• Other stocks in the sector such as Allystar Pharma (9926.HK) rose by 4% [0]
• GSK recorded a 30-40% increase in 2025 [0]
• Pro Medicus released strong revenue growth data [0]
• Reuters reported that the healthcare sector performed prominently in the Chinese stock market rebound, with positive market sentiment [0]

Due to data availability limitations, real-time quotes or daily price data for this stock cannot be obtained currently. However, it can be inferred from the fact that it is on the surging list that the stock has seen a significant price increase recently. Additionally, as it is not covered by major data sources, the stock may have the characteristic of low liquidity [0].

The rise of Da Jiankang International may be related to the overall investment enthusiasm in the healthcare sector, rather than specific fundamental factors of the individual stock itself. Against the background of the continuous positive performance of the sector, investor sentiment may drive short-term rises in such stocks.

1. Low Liquidity Risk
   : As the stock is not covered by major data providers, transaction liquidity may be low, with risks of large bid-ask spreads and intense price volatility [0]
2. Lack of Fundamental Support
   : Currently, there is no public fundamental data to support its rise, and the short-term market trend may lack sustainability [0]
3. Momentum Reversal Risk
   : If the overall sentiment of the sector cools down, the stock may face pressure for a rapid correction [0]

If the healthcare sector continues to maintain strong performance, this stock may continue to benefit from the sector’s trend.

This report analyzes the event of Da Jiankang International (02211.HK) being on the surging list of the East Money App hot list for Hong Kong stocks, pointing out that the stock’s popularity mainly stems from the overall strong performance of the healthcare sector. The report also highlights potential risks such as low liquidity, lack of fundamental support, and momentum reversal. Investors should carefully evaluate the relevant risks and make decisions based on their own investment strategies.